A case report on the association between QTc prolongation and remdesivir therapy in a critically ill patient

Prolonged Exposure to Remdesivir Inhibits the Human Ether-A-Go-Go-Related Gene Potassium Current

“…At admission, the patient's baseline QTc was 454 ms, but it increased to 532 ms after the initiation of remdesivir treatment. 22 The QTc decreased to 429 ms after the discontinuation of remdesivir at the end of the 5-day treatment course. 22 The major metabolite of remdesivir, GS-441524, has no antiviral activity.…”

“…22 The QTc decreased to 429 ms after the discontinuation of remdesivir at the end of the 5-day treatment course. 22 The major metabolite of remdesivir, GS-441524, has no antiviral activity. However, because of its poor cell permeability, it may accumulate in cells after the intracellular metabolism of remdesivir.…”

“…22 The QTc decreased to 429 ms after the discontinuation of remdesivir at the end of the 5-day treatment course. 22…”

“…The patient's QTc interval decreased to 429 ms after discontinuation of the 5-day course of remdesivir. Harbi et al 22 also reported a case of QT interval prolongation in an 80-year-old woman treated with remdesivir for COVID-19. At admission, the patient's baseline QTc was 454 ms, but it increased to 532 ms after the initiation of remdesivir treatment.…”

“…[16][17][18] In addition, case reports of QT interval prolongation and, in some cases, TdP associated with favipiravir, atazanavir, and remdesivir have emerged. [19][20][21][22] Additionally, several cases of prolonged QT interval and TdP have been reported to the FDA Adverse Event Reporting System in COVID-19 patients treated with remdesivir. As of the end of the third quarter of 2022, there were 1193 cardiac disorders associated with remdesivir use reported in the database, including 48 cases of QT prolongation and 4 cases of TdP.…”